Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012, Article ID 436174, 6 pages
http://dx.doi.org/10.1155/2012/436174
Clinical Study

Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo

1Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 00 Prague, Czech Republic
2Institute of Pathology, First Faculty of Medicine, Charles University in Prague, 128 00 Prague, Czech Republic
3Department of Obstetrics and Gynaecology, University Hospital Brno, 625 00 Brno, Czech Republic
4Department of Obstetrics and Gynaecology, Second Faculty of Medicine, Charles University in Prague, 150 06 Prague, Czech Republic

Received 7 March 2012; Revised 18 May 2012; Accepted 18 May 2012

Academic Editor: Faustino R. Pérez-López

Copyright © 2012 Petr Horak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [35 citations]

The following is the list of published articles that have cited the current article.

  • Javier Monleón Sancho, Eugenia Romaguera, Ainhoa Romero, Gema Higueras, Inmaculada Morcillo, and Sonia Fuster, “Ulipristal acetate, 5 mg: A new alternative,” Medicina Clinica, vol. 141, no. 1, pp. 40–46, 2013. View at Publisher · View at Google Scholar
  • Elke Bestel, and Jacques Donnez, “The potential of selective progesterone receptor modulators for the treatment of uterine fibroids,” Expert Review of Endocrinology & Metabolism, pp. 1–14, 2013. View at Publisher · View at Google Scholar
  • Marian Szamatowicz, and Jan Kotarski, “Selective Progesterone receptor modulator(ulipristal acetate - a new option in the pharmacological treatment of uterine fibroids in women,” Ginekologia Polska, vol. 84, no. 3, pp. 219–222, 2013. View at Publisher · View at Google Scholar
  • Lucy H.R. Whitaker, Alistair R.W. Williams, and Hilary O.D. Critchley, “Selective progesterone receptor modulators,” Current Opinion in Obstetrics and Gynecology, vol. 26, no. 4, pp. 237–242, 2014. View at Publisher · View at Google Scholar
  • Giuseppe Benagiano, Carlo Bastianelli, Manuela Farris, and Ivo Brosens, “Selective progesterone receptor modulators: an update,” Expert Opinion on Pharmacotherapy, pp. 1–13, 2014. View at Publisher · View at Google Scholar
  • Jacques Donnez, Francisco Vázquez, Janusz Tomaszewski, Kazem Nouri, Philippe Bouchard, Bart C.J.M. Fauser, David H. Barlow, Santiago Palacios, Olivier Donnez, Elke Bestel, Ian Osterloh, and Ernest Loumaye, “Long-term treatment of uterine fibroids with ulipristal acetate☆,” Fertility and Sterility, 2014. View at Publisher · View at Google Scholar
  • Jacques Donnez, Robert Hudecek, Olivier Donnez, Dace Matule, Hans-Joachim Arhendt, Janos Zatik, Zaneta Kasilovskiene, Mihai Cristian Dumitrascu, Hervé Fernandez, David H. Barlow, Philippe Bouchard, Bart C.J.M. Fauser, Elke Bestel, Paul Terrill, Ian Osterloh, and Ernest Loumaye, “Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids,” Fertility and Sterility, 2014. View at Publisher · View at Google Scholar
  • F. R. Pérez-López, “Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues,” Climacteric, pp. 1–5, 2014. View at Publisher · View at Google Scholar
  • Sławomir Woźniak, Piotr Szkodziak, Piotr Czuczwar, Ewa Wozńiakowska, Maciej Paszkowski, Paweł Milart, and Tomasz Paszkowski, “The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up,” Przeglad Menopauzalny, vol. 18, no. 1, pp. 18–21, 2014. View at Publisher · View at Google Scholar
  • N. M. Shamugiia, M. M. Sonova, L. V. Adamian, O. V. Zaĭrat'iants, O. N. Loginova, A. V. Laskevich, N. V. Donskova, and T. D. Alieva, “Control of bleeding, reduce the size of fibroids and reversible changes in the endometrium after ulipristal acetate treatment,” Problemy reproduktsii, no. 6, pp. 54, 2014. View at Publisher · View at Google Scholar
  • Lyubov Matytsina-Quinlan, and Laura Matytsina, “Abnormal excessive per vagina (PV) bleeding on Esmya-selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid,” BMJ Case Reports, vol. 2015, 2015. View at Publisher · View at Google Scholar
  • P. Czuczwar, S. Wozniak, P. Szkodziak, P. Milart, E. Wozniakowska, W. Wrona, and T. Paszkowski, “Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study,” Ultrasound in Obstetrics & Gynecology, 2015. View at Publisher · View at Google Scholar
  • Bo Sung Yoon, Seok Ju Seong, Dong Hyun Cha, Ji Yeon Kim, Mi-La Kim, Jeong Yun Shim, and Ji Eun Park, “,” European Journal of Obstetrics & Gynecology and Reproductive Biology, 2015. View at Publisher · View at Google Scholar
  • Ruyue Shao, Liaoqiong Fang, Ruoxi Xing, Yu Xiong, Liaoqiong Fang, and Zhibiao Wang, “Differential expression of estrogen receptor alpha and beta isoforms in multiple and solitary leiomyomas,” Biochemical And Biophysical Research Communications, vol. 468, no. 1-2, pp. 136–142, 2015. View at Publisher · View at Google Scholar
  • Sergio Haimovich, Marina Eliseeva, and Ospan A. Mynbaevpp. 129–151, 2015. View at Publisher · View at Google Scholar
  • Barbara Schütt, Andreas Kaiser, Marcus-Hillert Schultze-Mosgau, Christian Seitz, David Bell, Manuela Koch, and Beate Rohde, “Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women,” Human Reproduction, pp. dew140, 2016. View at Publisher · View at Google Scholar
  • Andrea Wagenfeld, Philippa T.K. Saunders, Lucy Whitaker, and Hilary O.D. Critchley, “Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies,” Expert Opinion on Therapeutic Targets, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  • Essam R. Othman, Dina M. M. Al-Adly, Dalia A. Elgamal, Nagwa Ghandour, and Sawsan El-Sharkawy, “Bisphenol A Concentrates Preferentially in Human Uterine Leiomyoma and Induces Proliferation in Rat Myometrium,” Reproductive Sciences, vol. 23, no. 4, pp. 508–514, 2016. View at Publisher · View at Google Scholar
  • Nathalie Esber, Clément Cherbonnier, Michèle Resche-Rigon, Abdallah Hamze, Mouad Alami, Jérôme Fagart, Hugues Loosfelt, Marc Lombès, and Nathalie Chabbert-Buffet, “Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model,” Hormones and Cancer, 2016. View at Publisher · View at Google Scholar
  • Christina Selgrad, and Olaf Ortmann, “Selektive Progesteronrezeptormodulatoren,” Gynäkologische Endokrinologie, 2016. View at Publisher · View at Google Scholar
  • Ya. Z. Zaidieva, and V. A. Glazkova, “Treatment in patients with uterine myoma: Facts and unsolved problems,” Rossiiskii vestnik akushera-ginekologa, vol. 16, no. 2, pp. 37, 2016. View at Publisher · View at Google Scholar
  • Karly P. Garnock-Jones, and Sean T. Duggan, “Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids,” Drugs, 2017. View at Publisher · View at Google Scholar
  • Myriam Safrai, Henry H. Chill, Adi Reuveni Salzman, and Asher Shushan, “Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas,” Obstetrics & Gynecology, vol. 130, no. 2, pp. 315–318, 2017. View at Publisher · View at Google Scholar
  • Lea Luketic, Lindsay Shirreff, Sari Kives, Grace Liu, Ramadan El Sugy, Nicholas Leyland, Meir Jonathon Solnik, and Ally Murji, “Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy?,” Journal of Minimally Invasive Gynecology, 2017. View at Publisher · View at Google Scholar
  • Christian Seitz, Žana Bumbuliene, Ana Rosa Costa, Oskari Heikinheimo, Andrea Heweker, Robert Hudeček, Yves Jacquemyn, Gian Benedetto Melis, Pooja Parashar, Tomasz Rechberger, Antonio Cano Sánchez, Bart Van Aken, János Zatik, and Kristina Gemzell-Danielsson, “Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids,” Contemporary Clinical Trials, 2017. View at Publisher · View at Google Scholar
  • Jean-Luc Brun, José Rajaonarison, Alizée Froeliger, Anne-Coline Monseau-Thiburce, Rado Randriamboavonjy, and Andrej Vogler, “Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy,” European Journal of Obstetrics & Gynecology and Reproductive Biology, 2017. View at Publisher · View at Google Scholar
  • Funlayo Odejinmi, Reeba Oliver, and Rebecca Mallick, “Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?,” Women's Health, pp. 174550571774021, 2017. View at Publisher · View at Google Scholar
  • Frank-Thorsten Hafner, Beate Rohde, Marcus-Hillert Schultze-Mosgau, Barbara Schuett, Frank Zollmann, Andreas Kaiser, and Joachim Hoechel, “Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women,” International Journal of Clinical Pharmacology and Therapeutics, vol. 55, no. 1, pp. 16–24, 2017. View at Publisher · View at Google Scholar
  • Dmitry Nikolayevich Voronin, Yulia Stanislavovna Antsiferova, Sergey Nikolayevich Nagornyi, Aleksey Nikolayevich Kirsanov, and Anna Ivanovna Malyshkina, “Impact of therapy with a selective progesterone receptor modulator on the synthesis of factors that regulate apoptosis and proteolysis in the myomatous nodules of patients with large leiomyoma,” Akusherstvo i Ginekologiya (Russian Federation), no. 2, pp. 64–70, 2017. View at Publisher · View at Google Scholar
  • H. H. Chill, M. Safrai, A. Reuveni Salzman, and A. Shushan, “The Rising Phoenix-Progesterone as the Main Target of the Medical Therapy for Leiomyoma,” BioMed Research International, vol. 2017, pp. 1–8, 2017. View at Publisher · View at Google Scholar
  • Silvia Baggio, Paola Pomini, Fabiana Galeone, Francesca Presti, Lorenza Santi, Ricciarda Raffaelli, and Massimo Franchi, “Influence of Ulipristal Acetate therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound,” Journal of Ultrasound in Medicine, 2018. View at Publisher · View at Google Scholar
  • Jinyoung Kim, Chiheum Cho, So-Jin Shin, Seungmee Lee, Jongwoo Baek, Jin Eui Lee, and Eunyoung, “Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix,” International Journal of Molecular Medicine, vol. 42, no. 4, pp. 1857–1864, 2018. View at Publisher · View at Google Scholar
  • Costantino Di Carlo, Antonio Maiorana, Ignazia Poidomani, Roberto Ravasio, and Adriano Vercellone, “Clinical and Economic Management of Uterine Fibroids: The Point of View of a Decision Makers Board,” Global & Regional Health Technology Assessment, vol. 3, no. 3, pp. GRHTA.5000223, 2018. View at Publisher · View at Google Scholar
  • Minnie Malik, William H. Catherino, Joy L. Britten, and Terrence D. Lewis, “Ulipristal Acetate Mediates Decreased Proteoglycan Expression Through Regulation of Nuclear Factor of Activated T-Cells (NFAT5),” Reproductive Sciences, 2018. View at Publisher · View at Google Scholar
  • N. I. Tapilskaya, A. S. Dukhanin, and R. I. Glushakov, “Influence of drug treatment of symptomatic uterine leiomyoma on the quality of life of women,” Problemy reproduktsii, vol. 24, no. 4, pp. 81, 2018. View at Publisher · View at Google Scholar